Schizophrenia with Adjunctive Treatment for Teen’s

NaBen vs Placebo as Adjunctive Treatment

Study Specific Details:

NaBen vs Placebo as adjunctive treatment with current antipsychotic.
7 visits over an 8 week period.
Fasting required (at least 8 hours) for screening visit.
Participants are reimbursed $50 for their time and travel at the end of each completed visit.

Any male or female between 12-17 of age.
DSM-IV or 5 diagnosis of schizophrenia based on the MINI.
Are clinically stable with residual symptoms, defined as a total score of greater or equal to 60 of PANSS and a score of great or equal to 40 for SANS.
Stable on current antipsychotic for 8 weeks prior to baseline and expected to remain unchanged during the study.
Depot or long acting antipsychotics need to be unchanged accordingly: 6 months - Olanzapine pamoate monohydrate (Zypadhera). 10 months - Invega, Paliperidone (Xeplion) and Aripiprazole (Maintena). At least 6 times duration of the reported half life of minimum of 4 months of other depot or long-acting anti-psychotics.

Diagnosis of mental retardation, dissociative disorder, bipolar disorder, MDD, schizoaffective disorder, schizophreniform, autistic disorder, or primary-induced psychotic disorder.
Other comorbid disorders are allowed as long as Schizophrenia is primary and the comorbid disorder(s) does not require medication.
Resistant to 2 different antipsychotics of adequate dose.
History of epilepsy, head trauma, or neurological illness other than Tourette's.
Use of depot antipsychotics in the past 6 months.
BMI > 35
Current substance abuse or positive urine illicit drug screening or history of substance dependence, including alcohol, in the past 3 months of screening.
History of allergic reaction to sodium benzoate

Want to learn more about Harmonex Neuroscience Research?